BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 20682141)

  • 1. Intrauterine device use among women with ovarian cancer: a systematic review.
    Zapata LB; Whiteman MK; Marchbanks PA; Curtis KM
    Contraception; 2010 Jul; 82(1):38-40. PubMed ID: 20682141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intrauterine device use among women with uterine fibroids: a systematic review.
    Zapata LB; Whiteman MK; Tepper NK; Jamieson DJ; Marchbanks PA; Curtis KM
    Contraception; 2010 Jul; 82(1):41-55. PubMed ID: 20682142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complications and continuation of intrauterine device use among commercially insured teenagers.
    Berenson AB; Tan A; Hirth JM; Wilkinson GS
    Obstet Gynecol; 2013 May; 121(5):951-958. PubMed ID: 23635730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Menstrual characteristics and ultrasonographic uterine cavity measurements predict bleeding and pain in nulligravid women using intrauterine contraception.
    Kaislasuo J; Heikinheimo O; Lähteenmäki P; Suhonen S
    Hum Reprod; 2015 Jul; 30(7):1580-8. PubMed ID: 25990577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intrauterine devices: an effective alternative to oral hormonal contraception.
    Prescrire Int; 2009 Jun; 18(101):125-30. PubMed ID: 19637436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intrauterine devices. The optimal long-term contraceptive method?
    Fortney JA; Feldblum PJ; Raymond EG
    J Reprod Med; 1999 Mar; 44(3):269-74. PubMed ID: 10202746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of contraceptive methods among women with endometrial hyperplasia: a systematic review.
    Whiteman MK; Zapata LB; Tepper NK; Marchbanks PA; Curtis KM
    Contraception; 2010 Jul; 82(1):56-63. PubMed ID: 20682143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of intrauterine devices in nulliparous women.
    Lohr PA; Lyus R; Prager S
    Contraception; 2017 Jun; 95(6):529-537. PubMed ID: 27591814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Body weight and composition in users of levonorgestrel-releasing intrauterine system.
    Dal'Ava N; Bahamondes L; Bahamondes MV; de Oliveira Santos A; Monteiro I
    Contraception; 2012 Oct; 86(4):350-3. PubMed ID: 22445431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Reasons for removal of intrauterine devices among women in general practice].
    Kolding L; Majeed HG
    Ugeskr Laeger; 2013 Mar; 175(13):884-6. PubMed ID: 23582897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acceptability of randomization to levonorgestrel versus copper intrauterine device among women requesting IUD insertion for contraception.
    Achilles SL; Chen BA; Lee JK; Gariepy AM; Creinin MD
    Contraception; 2015 Dec; 92(6):572-4. PubMed ID: 26297203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selection and performance of the levonorgestrel-releasing intrauterine system.
    Lähteenmäki P; Bardin CW; Elomaa K; Haukkamaa M; Kivijärvi A; Kuukankorpi A; Venhola M; Tuominen J
    Acta Obstet Gynecol Scand Suppl; 1997; 164():69-74. PubMed ID: 9225643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of copper intrauterine device with levonorgestrel-bearing intrauterine system for post-abortion contraception.
    Bilgehan F; Dilbaz B; Karadag B; Deveci CD
    J Obstet Gynaecol Res; 2015 Sep; 41(9):1426-32. PubMed ID: 26180028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levonorgestrel-releasing and copper intrauterine devices and the risk of breast cancer.
    Dinger J; Bardenheuer K; Minh TD
    Contraception; 2011 Mar; 83(3):211-7. PubMed ID: 21310281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perforation risk and intra-uterine devices: results of the EURAS-IUD 5-year extension study.
    Barnett C; Moehner S; Do Minh T; Heinemann K
    Eur J Contracept Reprod Health Care; 2017 Dec; 22(6):424-428. PubMed ID: 29322856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enlarged ovarian follicles in users of a levonorgestrel-releasing intrauterine system and contraceptive implant.
    Bahamondes L; Hidalgo M; Petta CA; Diaz J; Espejo-Arce X; Monteiro-Dantas C
    J Reprod Med; 2003 Aug; 48(8):637-40. PubMed ID: 12971147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of menorrhagia with a novel 'frameless' intrauterine levonorgestrel-releasing drug delivery system: a pilot study.
    Wildemeersch D; Schacht E
    Eur J Contracept Reprod Health Care; 2001 Jun; 6(2):93-101. PubMed ID: 11518454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levonorgestrel intrauterine device (IUD) exacerbation of PMS symptoms.
    Appiani FJ; Carroll BT
    Ann Clin Psychiatry; 2014 May; 26(2):146-7. PubMed ID: 24812652
    [No Abstract]   [Full Text] [Related]  

  • 19. Two years' experience with two levonorgestrel-releasing intrauterine devices and one copper-releasing intrauterine device: a randomized comparative performance study.
    Nilsson CG; Allonen H; Diaz J; Luukkainen T
    Fertil Steril; 1983 Feb; 39(2):187-92. PubMed ID: 6401636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A risk-benefit assessment of the levonorgestrel-releasing intrauterine system.
    Sturridge F; Guillebaud J
    Drug Saf; 1996 Dec; 15(6):430-40. PubMed ID: 8968696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.